WO1991018599A2 - 1,4-dihydropyridine zur anwendung bei der überwindung von arzneimittelresistenzen - Google Patents
1,4-dihydropyridine zur anwendung bei der überwindung von arzneimittelresistenzen Download PDFInfo
- Publication number
- WO1991018599A2 WO1991018599A2 PCT/EP1991/000957 EP9100957W WO9118599A2 WO 1991018599 A2 WO1991018599 A2 WO 1991018599A2 EP 9100957 W EP9100957 W EP 9100957W WO 9118599 A2 WO9118599 A2 WO 9118599A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- alkoxy
- hydrogen
- formula
- alkylene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a new application of known dihydropyridines.
- the dihydropyridines can be used in the pharmaceutical industry for the production of new drugs.
- 1,4-dihydropyridines described in more detail below are in an excellent position to increase the effectiveness of cytostatics against tumor cells (synergism) and to overcome the resistance of tumor cells to certain cytostatics.
- the resistance to resistance is not limited to resistance to cytostatics, but that resistance to other therapeutic agents (for example for the treatment of malaria) is also overcome.
- the invention therefore relates to the use of optically pure 1,4-dihydropyridines of the formula I.
- Rl is 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R2 is hydrogen, amino (NH 2 ), 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl,
- R3 denotes 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R4 denotes phenyl substituted by R41 and R42
- R41 hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-A1 alkyl, 1-4C-alkoxy, completely or partially substituted by fluorine-1-4C-alkoxy, 1-4C-alkoxycarbonyl, 2-5C-acyl, Amino or mono- or di-1-4C-alkylamino
- R42 is hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or partially substituted by fluorine-1-4C -Alkoxy, 1-4C-alkoxycarbonyl, 2-5C-acyl, amino or mono- or di-1-4C-alkylamino means
- El means oxygen (0), E2 straight-chain or branched 1-5C-alkylene, the grouping
- AI 2-4C-A1kylen ⁇ means
- A2 2-4C-alkylene or 2C-alkyleneoxy-2C-alkylene means, R5 and R6 together and including the nitrogen atom to which both are attached, a radical of the formula
- R7 is hydrogen (H) or aryl and R8 is aryl, or R7 and R8 together are diarylmethylene, R9 is diaryl-1-4C-alkyl and RIO is aryl-1-4C -alkyl means aryl for a ring of the formula
- R11 and R12 are the same or different and have the meaning hydrogen (H), 1-4C-alkyl, 1-4C-alkoxy, halogen, hydroxy, trifluoromethyl or together methylenedioxy, and their pharmacologically acceptable salts for the preparation of medicament agents that are intended to improve the effect of antibiotics and / or cytostatics and / or to overcome resistance to antibiotics and / or cytostatic agents.
- 1-6C-A1kyl is straight-chain or branched and means, for example, a hexyl, neopentyl, isopentyl, butyl, i-butyl, sec.-butyl, t-butyl, propyl, isopropyl or in particular Ethyl or methyl radical.
- 1-4C-A1kyl is straight-chain or branched and means, for example, a butyl, i-butyl, sec-butyl, t-butyl, propyl, isopropyl, ethyl or in particular methyl radical.
- 1-4C-alkoxy contains one of the 1-4C-alkyl radicals mentioned above. The methoxy and ethoxy radicals are preferred.
- 1-4C-Alkoxy-2-4C-alkyl represents a butyl, propyl or in particular ethyl radical which is substituted by one of the above-mentioned 1-4C-alkoxy radicals.
- the methoxyethyl radical is preferred.
- Halogen in the sense of the invention means bromine, fluorine and especially chlorine.
- 1-4C-Alkoxy which is wholly or partly substituted by fluorine is, for example, 1,1,2,2-tetrafluoroethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy or in particular difluoromethoxy.
- 1-4C-alkoxycarbonyl contains one of the 1-4C-alkoxy radicals mentioned above.
- 2-5C-acyl contains one of the 1-4C-al yl radicals mentioned above.
- the acetyl radical is preferred.
- mono- or di-1-4C-alkylamino contains one or two of the 1-4C-alkyl radicals mentioned above.
- Di-1-4C-alkylamino is preferred, and in particular dimethyl-, diethyl- or diisopropylamino.
- Straight-chain or branched 1-5C-alkylene is, for example, methylene (-CH 2 -), ethylene (-CH 2 -CH 2 -), trimethylene (-CH 2 -CH 2 -CH 2 -), tetramethylene (-CH 2 -CH 2 -CH 2 -CH 2 -), 1,2-dimethylethylene [-CH (CH 3 ) -CH (CH 3 ) -], 1,1-dimethylethylene [-C (CH 3 ) 2 -CH 2 - ], 1,1-dimethylpropylene [-C (CH 3 ) 2 -CH 2 -CH 2 -], 2,2-dimethylethylene [-CH 2 -C (CH 3 ) 2 -], isopropylidene [-C ( CH 3 ) 2 -] and 1-methylethylene [-CH (CH 3 ) -CH 2 -].
- 2-4C-alkylene stands for ethylene (-CH 2 -CH 2 -), trimethylene (-CH 2 -CH 2 -CH 2 -) and tetramethylene (-CH 2 -CH 2 -CH 2 -CH 2 -) , with ethylene being preferred.
- 2C-Alkyleneoxy-2C-alkylene stands for ethylene which is substituted by ethyleneoxy (-CH 2 -CH 2 -0-CH 2 -CH 2 -).
- Aryl stands for R11 and R12 substituted phenyl.
- aryl radicals which may be mentioned are: phenyl, 4-methoxyphenyl, 4-chlorophenyl, 4-me- thylphenyl, 4-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 3-methoxyphenyl, 2-methoxyphenyl, 2-ethoxyphenyl, 2-methylphenyl, 3-chloro-4-methylphenyl, 3,4- Dichlorophenyl, 3,6-dichlorophenyl, 2,4-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,4-methylenedioxyphenyl, 2-trifluoromethylphenyl and 3-trifluoromethylphenyl.
- Diaryl-1-4C-alkyl is 1-4C-alkyl which is substituted by two aryl radicals. Diaryl-1-4C-alkyl is especially diphenylmethyl (benzhydryl), or substituted benzhydryl, e.g. 4,4'-difluorobenzhydryl, 4,4'-dimethylbenzhydryl, 4,4'-dimethoxybenzhydryl or 4,4'Dichlorbenzhydryl.
- Aryl-1-4C-alkyl is 1-4C-alkyl which is substituted by aryl. Benzyl and 4-chlorobenzyl are particularly noteworthy.
- All salts with acids can be considered as salts.
- water-soluble and water-insoluble acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, a
- antibiotics which effectiveness is improved or for which resistance to them is overcome
- those antibiotics in which an (increasing) development of resistance can be observed are to be mentioned first and foremost.
- antibiotics against bacteria, mycoses, viruses and parasites, in particular against sporozoa, and above all malaria agents such as, for example, amodiaquin, mefloquine, .Pa aquin, primaquin, tebuquin, hydroxychloroquine and in particular chloroquine, may be mentioned.
- cytostatics are all customary cytostatics, such as, for example, alkylating agents of the nitrogen mustard type (e.g. chlora bucil, cyclophosphamide or Ifosfa - mid) or of the type of platinum complexes (e.g. cisplatin, carboplatin, iproplatin, oxaliplatin, oxoplatin, spiroplatin or tetraplatin), or intercalating substances of the anthracycline type (e.g.
- alkylating agents of the nitrogen mustard type e.g. chlora bucil, cyclophosphamide or Ifosfa - mid
- platinum complexes e.g. cisplatin, carboplatin, iproplatin, oxaliplatin, oxoplatin, spiroplatin or tetraplatin
- intercalating substances of the anthracycline type e.g.
- aclarubicin aclarubicin, daunorubicin, doxorubi- cin, esorubicin, epirubicin, idarubicin, pirarubicin or zorubicin), or around mitopodocides (e.g. etoposide), or around vinca alkaloids (e.g. vinblastine, vincristine, vindesin, vinepidine, vinleurosine, vinorelbin, vinrosidine or vinolidine, vintripin).
- mitopodocides e.g. etoposide
- vinca alkaloids e.g. vinblastine, vincristine, vindesin, vinepidine, vinleurosine, vinorelbin, vinrosidine or vinolidine, vintripin.
- One embodiment (embodiment a) of the invention is the use of optically pure 1,4-dihydropyridines of the formula I in which
- Rl is 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R2 is hydrogen, amino (NH 2 ), 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl,
- R3 denotes 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R4 denotes phenyl substituted by R41 and R42
- R41 is hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or partially substituted by fluorine-1-4C-alkoxy, 1-4C-alkoxycarbonyl, 2-5C-acyl, amino or mono- or di-1-4C-alkylamino
- R42 is hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or partially substituted by fluorine-1-4C- Alkoxy, l-4C-alkoxycarbonyl, 2-5C-acyl, amino or mono- or di-1-4C-alkylamino means
- El means oxygen (0), E2 straight-chain or branched 1-5C-alkylene or the grouping - A1-0-A2- means AI means 2-4C-alkylene,
- A2 2-4C-alkylene or 2C-alkyleneoxy-2C-alkylene means, R5 and R6 together and including the nitrogen atom to which both are attached, a radical of the formula
- R11 and R12 are the same or different and have the meaning hydrogen (H), 1-4C-alkyl, 1-4C-alkoxy, halogen, hydroxy, trifluoromethyl or together methylenedioxy, and their pharmacologically acceptable salts for the preparation of medicament agents that are intended to improve the effect of antibiotics and / or cytostatics and / or to overcome resistance to antibiotics and / or cytostatic agents.
- a further embodiment (embodiment b) of the invention is the use of optically pure 1,4-dihydropyridines of the formula I in which
- Rl is 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R2 is hydrogen, amino (NH 2 ), 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl,
- R3 denotes 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R4 denotes phenyl substituted by R41 and R42
- R41 is hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or partially fluorine-substituted 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 2-5C-acyl, amino or mono- or di-1-4C-alkylamino
- R42 denotes hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or partially substituted by fluorine-1-4C-alkoxy, 1-4C-Alkoxycarbonyl, 2-5C-acyl, amino or mono- or di-1-4C-alkylamino means
- El means oxygen (0)
- E2 means the grouping - (CH 2 ) -E- (CH 2 ) -
- R7 is hydrogen (H) or aryl and R8 is aryl, or R7 and R8 together are diaryl ethylene, R9 is diaryl-1-4C-alkyl and RIO is aryl-l- 4C-alkyl means, where aryl for a ring of the formula
- R11 and R12 are the same or different and have the meaning hydrogen (H), 1-4C-alkyl, 1-4C-alkoxy, halogen, hydroxy, trifluoromethyl or together methylenedioxy, and their pharmacologically acceptable salts for the preparation of medicament agents that are intended to improve the effect of antibiotics and / or cytostatics and / or to overcome resistance to antibiotics and / or cytostatic agents.
- a further embodiment (embodiment c) of the invention is the use of optically pure 1,4-dihydropyridines of the formula 1, in which
- Rl is 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R2 is hydrogen, amino (NH 2 ), 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl,
- R3 denotes 1-6C-alkyl or 1-4C-alkoxy-2-4C-alkyl
- R4 denotes phenyl substituted by R41 and R42
- R41 is hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or partially fluorine-substituted 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 2-5C-acyl, amino or mono- or di-1-4C-alkylamino
- R42 denotes hydrogen, hydroxy, halogen, nitro, cyano, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or partially substituted by fluorine-1-4C-alkoxy, 1-4C-alkoxycarbonyl, 2-5C-acyl, amino or mono- or di-1-4C-alkylamino means
- El means oxygen (0), E2 straight-chain or branched 1-5C-alkylene, the grouping
- A2 2-4C-alkylene or 2C-alkyleneoxy-2C-alkylene means, R5 and R6 together and including the nitrogen atom to which both are attached, a radical of the formula
- R7 means hydrogen (H) and R8 aryl, or R7 and R8 together mean diarylmethylene, R9 means diaryl-1-4C-alkyl and RIO aryl-1-4C-alkyl means where Aryl for a ring of the formula
- R11 and R12 are the same or different and have the meaning hydrogen (H), 1-4C-alkyl, 1-4C-alkoxy, halogen, hydroxy, trifluoromethyl or together methylenedioxy, and their pharmacologically acceptable salts for the preparation of medicament agents that are intended to improve the effect of antibiotics and / or cytostatics and / or to overcome resistance to antibiotics and / or cytostatic agents.
- R4 means phenyl substituted by R41 and R42, R41 means hydrogen, chlorine or nitro, R42 means hydrogen or chlorine, El means oxygen, E2 means ethylene or propylene,
- R7 is hydrogen or phenyl
- R8 is phenyl
- R7 and R8 together mean diphenylmethylene
- RIO means benzyl or 4-chlorobenzyl, and their pharmacologically acceptable salts.
- a preferred subject of the invention is the use according to the invention of compounds of the formula I in which Rl is 1-4C-alkyl, R2 is 1-4C-alkyl, R3 is 1-4C-alkyl, R4 is 3-nitrophenyl, El is oxygen, E2 Means ethylene or propylene
- A is -CH 2 -CH 2 -C (R7) R8-CH 2 -CH 2 -, R7 is phenyl and R8 is phenyl, and their pharmacologically acceptable salts.
- the compounds of the formula I are known, for example from EP-A-242829, EP-A-296 316, DE-OS 36 27 742 and W088 / 07531.
- the compounds of the formula I and their pharmacologically acceptable salts have valuable properties which make them commercially usable in the sense according to the invention. They improve the effect of antibiotics and cytostatics in a synergistic manner and, moreover, they are able to overcome existing resistances to antibiotics and cytostatics that arise during the course of therapy.
- the invention thus relates to the use of compounds of the formula I in combination with antibiotics or cytostatics in antibiotic and / or cytostatic therapy.
- the invention furthermore relates to the use of compounds of the formula I for the production of medicaments which are to be used in combination with antibiotics or cytostatics in antibiotic and / or cytostatic therapy.
- the dose of the cytostatics administered can be reduced, which leads to a significant reduction in the toxic side effects, and that the number increases of the usable cytostatic agents, so that the cytostatic agent that is optimally suitable for the particular tumor and the particular patient can be specifically selected.
- the ratio of compound I to antibiotic or cytostatic agent depends on the disease to be treated, the disease state of the patient and the antibiotic or cytostatic agent used. It has generally proven to be advantageous here for the compounds of the formula I to be administered orally in a daily dose of about 0.5 to 30 mg / kg of body weight, and for intravenous administration in a daily dose of about 0.1 to 10 mg / kg of body weight , if necessary in the form of several single doses or as a continuous infusion to achieve the desired result.
- the antibiotics or cytostatics are administered in the usual, but preferably in lower, doses.
- the tumor cell lines M0LT / VCR-5x9 (starting density: 1.14 x 10 cells / ml), MOLT / DAU-8 (starting density: 1.01 x 10 cells / ml) and CCRF CEM VCR1000 + resistant to the cytostatics vincristine and daunomycin (Initial density: 2.00 x 10 cells / ml) were incubated for 72.5 to 73.25 hours according to the following test pattern:
- cytostatic concentrations used for the individual cell lines were:
- Daunomycin 10 M (at MOLT / DAU-8)
- Vincristine 1.08 x lo " M (for CCRF CEM VCR1000 +)
- the tumor cell lines are resistant to the cytotoxic '.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/949,870 US5514664A (en) | 1990-05-26 | 1991-05-22 | 1,4-dihydropyridines for application in combatting resistance to drugs |
JP91509728A JPH05507480A (ja) | 1990-05-26 | 1991-05-22 | 医薬品抵抗性の克服の際に使用するための1,4―ジヒドロピリジン |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4017061 | 1990-05-26 | ||
DEP4017061.6 | 1990-05-26 | ||
CH247990 | 1990-07-26 | ||
CH2479/90-6 | 1990-07-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991018599A2 true WO1991018599A2 (de) | 1991-12-12 |
WO1991018599A3 WO1991018599A3 (de) | 1992-02-20 |
Family
ID=25690564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1991/000957 WO1991018599A2 (de) | 1990-05-26 | 1991-05-22 | 1,4-dihydropyridine zur anwendung bei der überwindung von arzneimittelresistenzen |
Country Status (5)
Country | Link |
---|---|
US (1) | US5514664A (de) |
EP (1) | EP0531369A1 (de) |
JP (1) | JPH05507480A (de) |
AU (1) | AU7885991A (de) |
WO (1) | WO1991018599A2 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686879A1 (fr) * | 1992-02-05 | 1993-08-06 | Adir | Nouveaux composes de 1,4-dihydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant. |
US5403847A (en) * | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
US5578611A (en) * | 1992-11-13 | 1996-11-26 | Synaptic Pharmaceutical Corporation | Use of α-1C specific compounds to treat benign prostatic hyperplasia |
US5767131A (en) * | 1993-04-05 | 1998-06-16 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
US6015819A (en) * | 1992-11-13 | 2000-01-18 | Synaptic Pharmaceutical Corporation | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376514B1 (en) * | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
EP1651612B9 (de) | 2003-07-22 | 2012-09-05 | Astex Therapeutics Limited | 3,4-disubstituierte 1h-pyrazol-verbindungen und deren verwendung als cyclin-abhängige kinase (cdk) und glycogen synthase kinase-3 (gsk-3) modulatoren |
DE602004027824D1 (de) * | 2003-09-25 | 2010-08-05 | Astellas Pharma Inc | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
WO2006077428A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
MX2007008810A (es) * | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
EP2026805A1 (de) * | 2006-05-08 | 2009-02-25 | Astex Therapeutics Limited | Pharmazeutische kombinationen aus diazolderivaten zur krebsbehandlung |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3627742A1 (de) * | 1985-08-20 | 1987-02-26 | Byk Gulden Lomberg Chem Fab | Substituierte 1,4-dihydropyridin-3-carbonsaeurederivate |
WO1989007443A1 (en) * | 1988-02-19 | 1989-08-24 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases |
-
1991
- 1991-05-22 AU AU78859/91A patent/AU7885991A/en not_active Abandoned
- 1991-05-22 EP EP91909944A patent/EP0531369A1/de not_active Withdrawn
- 1991-05-22 US US07/949,870 patent/US5514664A/en not_active Expired - Fee Related
- 1991-05-22 WO PCT/EP1991/000957 patent/WO1991018599A2/de not_active Application Discontinuation
- 1991-05-22 JP JP91509728A patent/JPH05507480A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3627742A1 (de) * | 1985-08-20 | 1987-02-26 | Byk Gulden Lomberg Chem Fab | Substituierte 1,4-dihydropyridin-3-carbonsaeurederivate |
WO1989007443A1 (en) * | 1988-02-19 | 1989-08-24 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases |
Non-Patent Citations (9)
Title |
---|
Am. J. Trop. Med. Hyg., Band 39, Nr. 1, 1988, Baltimore, US; G.H. Jacobs et al.: "Ultrastructural study of the effects of chloroquine and verapamil on Plasmodium falciparum", Seiten 15-20, siehe Zusammenfassung * |
Cancer Research, Band 50, Nr. 5, 1. M{rz 1990, Philadelphia, US; H.M. Schuller et al.: "Succesful chemotherapy of experimental neuroendocrine lung tumors in hamsters with an antagonist of Ca2+/calmodulin", Seiten 1645-1649, siehe Zusammenfassung; Diskussion * |
Cell, Band 57, 16. Juni 1989, Cell Press, Cambridge, US; S.J. Foote et al.: "Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum", Seiten 921-930, siehe Zusammenfassung * |
International Journal of Cancer, Band 47, Nr. 6, 1. April 1991, Wiley-Liss, Inc. New York, US; J. Hofmann et al.: "B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance", Seiten 870-874, siehe Zusammenfassung * |
Nature, Band 345, 17. Mai 1990, London, GB; C. Newbold: "Malaria. The path of drug resistance", Seiten 202-203, siehe den ganzen Artikel * |
Nature, Band 345, 17. Mai 1990, London, GB; T.E. Wellems et al.: "Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross", Seiten 253-256, siehe Zusammenfassung * |
Naunyn-Schmiedeberg's Arch Pharmacol., Band 341, (Suppl.) 1990, Berlin, DE; siehe Seite R45, Zusammenfassung Nr. 177, F. Abdallah et al.: "Inhibition of cell proliferation by dihydropyridine derivatives" & Deutsche Gesellschaft f}r Pharmakologie und Toxikologie, "Abstracts of the 31st Spring Meeting", 13-16. M{rz 1990, Mainz (Kat. O) * |
Proc. Natl. Acad. Sci. USA, Band 84, Oktober 1987, Washington, US; L.W. Scheibel et al.: "Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falci parum): implications for drug", Seiten 7310-7314, siehe den ganzen Artikel, insbesondere Seite 7310 * |
Proceedings of the eighty-first annual meeting of the American Association for Cancer Research, Band 31, M{rz 1990, Washington, US; H.M. Schuller et al.: "Selective chemotherapeutic effect of the Ca2+/calmodulin antagonist B859-35 on induced neuroendocrine lung cancer in hamsters", siehe Seite 350, Zusammenfassung 2074 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686879A1 (fr) * | 1992-02-05 | 1993-08-06 | Adir | Nouveaux composes de 1,4-dihydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant. |
EP0556092A1 (de) * | 1992-02-05 | 1993-08-18 | Adir Et Compagnie | 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
US5403847A (en) * | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
US5578611A (en) * | 1992-11-13 | 1996-11-26 | Synaptic Pharmaceutical Corporation | Use of α-1C specific compounds to treat benign prostatic hyperplasia |
US5780485A (en) * | 1992-11-13 | 1998-07-14 | Synaptic Pharmaceutical Corporation | Use of α1c specific compounds to treat benign prostatic hyperplasia |
US6015819A (en) * | 1992-11-13 | 2000-01-18 | Synaptic Pharmaceutical Corporation | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
US6602888B2 (en) | 1992-11-13 | 2003-08-05 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperplasia |
US5767131A (en) * | 1993-04-05 | 1998-06-16 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
US6310076B1 (en) | 1993-04-05 | 2001-10-30 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
US6608086B2 (en) | 1993-04-05 | 2003-08-19 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
US5990128A (en) * | 1994-04-13 | 1999-11-23 | Synaptic Pharmaceutical Corporation | α1C specific compounds to treat benign prostatic hyperplasia |
Also Published As
Publication number | Publication date |
---|---|
WO1991018599A3 (de) | 1992-02-20 |
JPH05507480A (ja) | 1993-10-28 |
US5514664A (en) | 1996-05-07 |
EP0531369A1 (de) | 1993-03-17 |
AU7885991A (en) | 1991-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991018599A2 (de) | 1,4-dihydropyridine zur anwendung bei der überwindung von arzneimittelresistenzen | |
DE60011391T2 (de) | Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen | |
US5219865A (en) | Pharmaceutical combination for the prophylaxis and therapy of malaria | |
DE69918819T2 (de) | Antikrebs-zusammensetzung enthaltend eine synergistische kombination bestehend aus einem anthracyclin-derivat mit einen camptothecin-derivat | |
JP2010270124A (ja) | 抗癌組み合わせ | |
DE60128003T2 (de) | Camptothecin derivate | |
WO1991015484A1 (de) | Pyridine als arzneimittel | |
DE3319347A1 (de) | Arzneimittel zur verstaerkung der therapeutischen wirkung von antitumormitteln und deren verwendung | |
AU2016307752B2 (en) | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same | |
WO1991015485A1 (de) | Neue pyridinester | |
EP0290959A2 (de) | Arzneimittelkombination zur Prophylaxe und Therapie von Malaria | |
WO1989007443A1 (en) | Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases | |
EP0268100B1 (de) | Wirkstoffe zur Anwendung bei der Behandlung von Tumoren | |
US5696131A (en) | Treatment of cancers | |
DE60318561T2 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
EP0322643A1 (de) | Arzneimittel enthaltend in Kombination Interferon und 1-Desoxy-piperidinosen, Verfahren zu deren Herstellung und deren Verwendung | |
AU740642B2 (en) | Pharmaceutical compositions containing cinchonine dichlorhydrate | |
WO1991009846A1 (de) | Neue dihydropyridine | |
DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
EP2406218A1 (de) | Pharmazeutische kombination aus 5-fluorouracil und einem 1,4-dihydropyridin-derivat und ihre verwendung zur behandlung von krebs | |
WO1993011766A1 (de) | 1,4-dihydropyridine zur anwendung bei der behandlung von dermatosen | |
JPH0873355A (ja) | 抗マラリア薬耐性克服剤 | |
DE1670061C (de) | 2 (2' Pyndyloxy)-athylguamdin und Verfahren zu dessen Herstellung | |
DE2800508C3 (de) | 6,77-Dimethoxy-2-thiomorpholino-4chinazolinamin | |
DE3390386T1 (de) | Antitumor-Mittel, Verfahren zur Tumor-Therapie und Verwendung zur Tumor-Therapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA DE FI HU JP KR NO PL SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA DE FI HU JP KR NO PL SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991909944 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991909944 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991909944 Country of ref document: EP |